ClinicalTrials.gg
Active, not recruitingNCT04482309DPT02Updated Nov 2, 2026

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

A Phase 2 interventional study of Trastuzumab deruxtecan in Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer and Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer, sponsored by AstraZeneca. Active, not recruiting at 89 sites in 17 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Nov 2, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
477
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Pancreatic Neoplasms by AstraZeneca — 3 open to participants now, 5 under way, none of them phase 3. Pancreatic Neoplasms · AstraZeneca.

Enrollment
3rd of 14
477 · median 69
Started
2020
with 1 other
Phase 2
4 of 19
none open now
Registered
12th of 19
by date

Among the 19 studies in Pancreatic Neoplasms by AstraZeneca, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 12th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 19 studies in Pancreatic Neoplasms by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pancreatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.

This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer), B) any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer), C) HER2 IHC 2+ or 1+ endometrial cancer, D) HER2 IHC 2+ or 1+ ovarian cancer, and E) HER2 IHC 2+ or 1+ cervical cancer.

Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.

03

Conditions studied

  • Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
  • Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Keywords

  • T-DXd, DS-8201a, Trastuzumab Deruxtecan, HER2
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced, unresectable, or disease based on most recent imaging.
  • Part 1:The respective cohorts for patient inclusion are:

    • Cohort 1: Biliary tract cancer
    • Cohort 2: Bladder cancer
    • Cohort 3: Cervical cancer
    • Cohort 4: Endometrial cancer
    • Cohort 5: Epithelial ovarian cancer
    • Cohort 6: Pancreatic cancer
    • Cohort 7: Rare tumors: This cohort will consist of patients with tumors that express , excluding the tumors mentioned above, and breast, non-small cell lung cancer, gastric cancer, and colorectal cancer.
  • Part 2:The respective cohorts for patient inclusion are:

    • Cohort A: Metastatic or advanced solid tumors that are HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer). Patients with non-small cell lung cancer can be included.
    • Cohort B: Metastatic or advanced solid tumors that are HER2 IHC 2+/ISH+ any tumor type (excluding breast, gastric cancer, and colorectal cancer). Patients with non-small cell lung cancer can be included.
    • Cohort C: Metastatic or advanced solid endometrial cancer that is HER2 IHC 2+ or 1+.
    • Cohort D: Metastatic or advanced ovarian cancer that is HER2 IHC 2+ or 1+.
    • Cohort E: Metastatic or advanced solid cervical cancer that is HER2 IHC 2+ or 1+.
  • Progressed following prior treatment or who have no satisfactory alternative treatment option.
  • Prior HER2 targeting therapy is permitted.
  • HER2 expression scored using current ASCO/CAP guidelines for scoring HER2 for gastric cancer.

    • Part 1: IHC 3+ or IHC 2+ by local or central assessment
    • Part 2: IHC and ISH results by central assessment as pre-defined for each cohort
  • Has measurable target disease assessed by the Investigator based on version 1.1.
  • Has protocol- defined adequate organ function including cardiac, renal and hepatic function.

Exclusion criteria

Exclusion Criteria:

  • History of non-infectious pneumonitis/ILD that required , current ILD, or where suspected ILD that cannot be ruled out by imaging at screening
  • Lung-specific intercurrent severe illnesses
  • Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
  • Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART
  • Known Somatic DNA mutation of (ERBB2) without tumoral HER2 protein expression.
  • Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, adenocarcinoma of the gastric body or gastro-esophageal junction, or non-small cell lung cancer for Part 1. For Part 2, patients with primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, adenocarcinoma of the gastric body or gastro-esophageal junction will be excluded.
  • Medical conditions that may interfere with the subject's participation in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
477 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1

    Biliary tract cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1 Cohort 2

    Bladder cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1 Cohort 3

    Cervical cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1 Cohort 4

    Endometrial cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1 Cohort 5

    Ovarian cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1 Cohort 6

    Pancreatic cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 1 Cohort 7

    Rare tumors

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort A

    Any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer)

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort B

    Any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer)

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort C

    HER2 IHC 2+ or 1+ endometrial cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort D

    HER2 IHC 2+ or 1+ ovarian cancer

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort E

    HER2 IHC 2+ or 1+ cervical cancer

    Drug: Trastuzumab deruxtecan

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.

    Time frame: An average of approximately 6 months

Secondary outcomes

  1. Duration of response (DoR)

    DOR is defined as the time from the date of first documented response until the date of documented progression or death.

    Time frame: An average of approximately 6 months

  2. Disease control rate (DCR)

    DCR is the percentage of subjects who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD).

    Time frame: An average of approximately 6 months

  3. Progression free survival (PFS)

    PFS is the time from date of first dose of study treatment until the date of objective disease progression or death.

    Time frame: An average of approximately 6 months

  4. Proportion of patients alive and progression-free at 6 months and 12 months

    The proportion of patients alive and progression-free at 6 and 12 months (Kaplan-Meier estimates).

    Time frame: Up to 12 months

  5. Overall survival (OS)

    OS is the time from date of first dose of study treatment until death due to any cause.

    Time frame: An average of approximately 14 months

  6. Proportion of patients alive at 6 and 12 months

    The proportion of patients alive at 6 and 12 months (Kaplan-Meier estimates).

    Time frame: Up to 12 months

  7. Occurrence of adverse events (AEs) and serious adverse events (SAEs)

    Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0.

    Time frame: An average of approximately 8 months

  8. Pharmacokinetics (PK) assessed by serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd, total anti-HER2 antibody and MAAA-1181a

    Time frame: An average of approximately 8 months

  9. The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd

    Individual participant data and descriptive statistics will be provided for data at each time point.

    Time frame: An average of approximately 6 months

07

Study locations

89 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Muncie, Indiana 47303, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Middletown, New Jersey 07748, United States
  • Research Site
    Harrison, New York 10604, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Auchenflower, 4066, Australia
  • Research Site
    Blacktown, 2148, Australia
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Vitória, 29043-272, Brazil
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    Prague, 180 81, Czechia
  • Research Site
    Delhi, 110085, India
  • Research Site
    Gūrgaon, 122001, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Rome, 168, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Amsterdam, 1066CX, Netherlands
  • Research Site
    Delft, 2625 AD, Netherlands
  • Research Site
    Groningen, 9700, Netherlands
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Krakow, 31-501, Poland
  • Research Site
    Poznan, 60-355, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Kaluga, 248007, Russia
  • Research Site
    Moscow, 115419, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 117997, Russia
  • Research Site
    Moscow, 121205, Russia
  • Research Site
    Moscow, 143423, Russia
  • Research Site
    Moscow, 143442, Russia
  • Research Site
    Saint Petersburg, 195271, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 5505, South Korea
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Valencia, 46014, Spain
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 736, Taiwan
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taipei, 10449, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkok, 10210, Thailand
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Chiang Mai, 50200, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Khon Kaen, 40002, Thailand
  • Research Site
    Muang, 50200, Thailand
  • Research Site
    Ongkharak, 26120, Thailand
  • Research Site
    London, SW2 6JJ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Publications

  • Lee JY, Oaknin A, Manso L, Gonzalez-Martin A, Lugowska I, Lorusso D, Banerjee S, Liao JB, Lu CH, Prasongsook N, Melichar B, Anoka C, Jung L, Michelini F, Puvvada S, Meric-Bernstam F, Makker V. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. J Gynecol Oncol. 2026 May;37(3):e65. doi: 10.3802/jgo.2026.37.e65. Epub 2026 May 6. PubMed 42135959 ↗
  • Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11. PubMed 39261417 ↗
  • Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. PubMed 37870536 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Mar 2027, 79 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 79 months is above that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 22, 2020
StartActual
Aug 18, 2020
Primary completionEst.
Mar 23, 2027
CompletionEst.
Mar 23, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Site · Gūrgaon, India
Show 1 removed
  • Research Site · Gurgaon, India
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Research Site · Gūrgaon, India
    Show 1 removed
    • Research Site · Gurgaon, India
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04482309
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Aug 18, 2020
Primary completion
Mar 23, 2027 (estimated)
Completion
Mar 23, 2027 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion